Coherus Oncology vs Siga Technologies
Siga Technologies is the larger business, with $94.6m of revenue in fiscal 2025 against $42.2m for Coherus Oncology (2.2 times as much). Coherus Oncology grew faster (59.8% against -31.8%). Coherus Oncology kept more of each dollar of sales as profit: a net margin of 398.4% against 24.6%. Coherus Oncology carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Coherus OncologyCHRS, 2025 | Siga TechnologiesSIGA, 2025 |
|---|---|---|
| Revenue | $42.2m | $94.6m |
| Revenue growth | 59.8% | -31.8% |
| Net income | $168m | $23.3m |
| Operating margin | -429.5% | 25.1% |
| Net margin | 398.4% | 24.6% |
| Return on equity | — | 11.2% |
| Free cash flow | −$139m | $43.1m |
| Cash | $88.9m | $155m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | $0.60 |
| Dividend yield | — | 20.6% |
| Share buybacks | — | $0 |
| Employees | 147 | 49 |
| Market value | $116m | $212m |
| Price vs our value range | — | Below our value range |
| Moat score | 19 (Weak) | 71 (Strong) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |